DZIUREK / SHUTTERSTOCK.COM
How will the OECD’s Modified Nexus Approach to innovator-friendly tax regimes such as the UK’s patent box affect the life sciences industry? LSIPR investigates.
You could say it worked well.
Soon after the UK government announced that it would introduce the patent box, a tax break for innovative companies, GlaxoSmithKline (GSK) and AstraZeneca, the country’s largest pharmaceutical companies, announced plans to expand their operations at home.
GSK reportedly poured £500 million ($771 million) into a manufacturing facility in the UK, created 1,000 new jobs and constructed a new factory, while AstraZeneca invested £120 million, also in a new factory.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
OECD, tax, biotechnology, IP, BEPs,